Cargando…

Glucocorticoid-Treated Mice Are an Inappropriate Positive Control for Long-Term Preclinical Studies in the mdx Mouse

BACKGROUND: Dmd(mdx) (mdx) mice are used as a genetic and biochemical model of dystrophin deficiency. The long-term consequences of glucocorticoid (GC) treatment on dystrophin-deficient skeletal and heart muscle are not yet known. Here we used systematic phenotyping to assess the long-term consequen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sali, Arpana, Guerron, Alfredo D., Gordish-Dressman, Heather, Spurney, Christopher F., Iantorno, Micaela, Hoffman, Eric P., Nagaraju, Kanneboyina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317932/ https://www.ncbi.nlm.nih.gov/pubmed/22509280 http://dx.doi.org/10.1371/journal.pone.0034204

Ejemplares similares

Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse
por: Spurney, Christopher F., et al.
Publicado: (2010)

The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice
por: Sali, Arpana, et al.
Publicado: (2013)

Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the mdx Mouse Model of Duchenne Muscular Dystrophy
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Correction: Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the Dystrophin Deficient mdx mice
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Correction: Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the Dystrophin Deficient mdx mice
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Correction: Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the Dystrophin Deficient mdx mice
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Non-Invasive MRI and Spectroscopy of mdx Mice Reveal Temporal Changes in Dystrophic Muscle Imaging and in Energy Deficits
por: Heier, Christopher R., et al.
Publicado: (2014)

Membrane Sealant Poloxamer P188 Protects Against Isoproterenol Induced Cardiomyopathy in Dystrophin Deficient Mice
por: Spurney, Christopher F, et al.
Publicado: (2011)

Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice
por: Ziemba, Michael, et al.
Publicado: (2021)

Omigapil Treatment Decreases Fibrosis and Improves Respiratory Rate in dy(2J) Mouse Model of Congenital Muscular Dystrophy
por: Yu, Qing, et al.
Publicado: (2013)

Muscular dystrophy in the mdx mouse is a severe myopathy compounded by hypotrophy, hypertrophy and hyperplasia
por: Duddy, William, et al.
Publicado: (2015)

IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse
por: Kostek, Matthew C, et al.
Publicado: (2012)

Non-invasive Optical Imaging of Muscle Pathology in mdx Mice Using Cathepsin Caged Near-Infrared Imaging
por: Baudy, Andreas R., et al.
Publicado: (2010)

Effect of the IL-1 Receptor Antagonist Kineret(®) on Disease Phenotype in mdx Mice
por: Benny Klimek, Margaret E., et al.
Publicado: (2016)

Characterization of Dysferlin Deficient SJL/J Mice to Assess Preclinical Drug Efficacy: Fasudil Exacerbates Muscle Disease Phenotype
por: Rayavarapu, Sree, et al.
Publicado: (2010)

Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model
por: Jahnke, Vanessa E, et al.
Publicado: (2012)

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
por: Tatem, Kathleen S., et al.
Publicado: (2014)

“Of Mice and Measures”: A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic: First Workshop Report: Examining current findings and opportunities around the emerging D2.B10-Dmd(mdx)/J (D2/mdx) model in context of the classic C57BL/10ScSn-Dmd(mdx)/J (Bl10/mdx)
por: Gordish-Dressman, Heather, et al.
Publicado: (2018)

Proteomic profiling of glucocorticoid-exposed myogenic cells: Time series assessment of protein translocation and transcription of inactive mRNAs
por: Reeves, Erica KM, et al.
Publicado: (2009)

Discovery of potential urine-accessible metabolite biomarkers associated with muscle disease and corticosteroid response in the mdx mouse model for Duchenne
por: Thangarajh, Mathula, et al.
Publicado: (2019)

The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse
por: Zhang, Aiping, et al.
Publicado: (2015)

Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes
por: Hoffman, Eric P., et al.
Publicado: (2018)

Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease
por: Heier, Christopher R, et al.
Publicado: (2016)

VBP15, a Glucocorticoid Analogue, Is Effective at Reducing Allergic Lung Inflammation in Mice
por: Damsker, Jesse M., et al.
Publicado: (2013)

Neurodevelopmental Needs in Young Boys with Duchenne Muscular Dystrophy (DMD): Observations from the Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study (DNHS).
por: Thangarajh, Mathula, et al.
Publicado: (2018)

Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy
por: Willmann, Raffaella, et al.
Publicado: (2017)

Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45–55 With a Cocktail of Vivo-Morpholinos in Mdx52 Mice
por: Echigoya, Yusuke, et al.
Publicado: (2015)

Effect of TNF-α on human ARPE-19-secreted proteins
por: An, Eunkyung, et al.
Publicado: (2008)

Skeletal, cardiac, and respiratory muscle function and histopathology in the P448Lneo− mouse model of FKRP-deficient muscular dystrophy
por: Yu, Qing, et al.
Publicado: (2018)

Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy
por: Hathout, Yetrib, et al.
Publicado: (2019)

Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
por: Heemskerk, Hans, et al.
Publicado: (2010)

The D2.mdx mouse as a preclinical model of the skeletal muscle pathology associated with Duchenne muscular dystrophy
por: Hammers, David W., et al.
Publicado: (2020)

Effect of endurance exercise on microRNAs in myositis skeletal muscle—A randomized controlled study
por: Boehler, Jessica F., et al.
Publicado: (2017)

VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects
por: Heier, Christopher R, et al.
Publicado: (2013)

Aquaporin 4 Expression in the mdx Mouse Diaphragm
por: Hara, Hajime, et al.
Publicado: (2011)

Decrease in Prosaposin in the Dystrophic mdx Mouse Brain
por: Gao, Hui-ling, et al.
Publicado: (2013)

Cognitive impairment appears progressive in the mdx mouse
por: Bagdatlioglu, Emine, et al.
Publicado: (2020)

A comparison of the bone and growth phenotype of mdx, mdx:Cmah(−/−) and mdx:Utrn(+/−) murine models with the C57BL/10 wild-type mouse
por: Wood, Claire L., et al.
Publicado: (2020)

Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children
por: Hathout, Yetrib, et al.
Publicado: (2016)

Temporal changes in magnetic resonance imaging in the mdx mouse
por: Pratt, Stephen JP, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_n4rn6gemqhafpd2d9fi808hvjm